Glucocorticoid-induced Atrophy in Bone and Muscle

糖皮质激素引起的骨和肌肉萎缩

基本信息

  • 批准号:
    10463792
  • 负责人:
  • 金额:
    $ 33.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

Excess of glucocorticoids (GC) has devastating effects on the musculoskeletal system with 30-50% of long-term treated patients exhibiting bone fractures. GC induce bone loss by increasing resorption and decreasing for- mation; and also induce muscle loss and weakness leading to higher incidence of falls. The combined effects on bone and muscle largely account for the increased fracture risk with GC. Inhibition of resorption (the current standard of care) stops bone loss; but, markedly reduces bone turnover resulting in microdamage accumulation with potential development of osteonecrosis of the jaw and atypical fractures; and does not prevent muscle weakness. Therefore, osteoanabolic therapeutic approaches that build new bone and simultaneously interfere with GC actions in muscle are sorely needed. Work leading to this application demonstrates that GC increase the expression of the proteasomal degradation inducers E3 ubiquitin ligases atrogin1, MuRF1, and MUSA1 (atrogenes) in both muscle and bone, a novel finding as atrogenes are traditionally considered muscle-specific. In addition, inhibition of proteasomal degradation with bortezomib prevents GC-induced osteoblast apoptosis and, further, bortezomib or silencing of MuRF1 in osteoblasts prevents GC-induced decrease in matrix mineral- ization in vitro. Moreover, activation of the Vitamin D receptor (VDR) has beneficial musculoskeletal effects and might prevent falls. We found that VDR signaling prevents GC-induced: 1) atrogene expression in bone and muscle ex vivo, 2) the increase in Sost expression ex vivo, and 3) apoptosis of osteoblasts and osteocytes in vitro. Based on these lines of evidence, we hypothesize that atrogene upregulation is a common mechanism underlying GC actions in bone and muscle and that interventions that interfere with atrogene expression or function will prevent GC harmful actions in both tissues. We will test this hypothesis using in vivo, ex vivo, and in vitro approaches. Aim1 will examine whether genetic loss of expression or function of MuRF1 or pharmaco- logic inhibition of the proteasome with bortezomib interfere with atrogene expression/function and counteracts GC-induced bone or muscle atrophy in vivo, in prevention and restoration models; and whether genetic deletion of Notch or FoxO1, or pharmacologic inhibition of Notch signaling prevents muscle atrophy induced by GC. Aim2 will investigate the mechanism of action of VDR signaling on GC-induced bone and muscle atrophy, by examin- ing whether VDR signaling (induced with 1,25-D3 or eldecalcitol/ED-17, a VDR ligand with reduced hypercalce- mic action) counteracts GC regulation of proteostasis, mitochondrial dynamics and cellular energetics in bone and muscle; by studying whether VDR signaling reverses the inhibition of anabolic signaling and the stimulation of catabolic signaling mediated by Sost upregulation induced by GC in bone, in mice with genetic deletion of the VDR in muscle (HSA-MerCreMer) and respective control littermates; and by determining whether VDR signaling prevents GC effects on muscle fiber type composition (glycolytic versus oxidative), and/or preserves Ryn recep- tor-mediated muscle contraction.
过量的糖皮质激素(GC)对肌肉骨骼系统有破坏性的影响,30-50%的长期服用 治疗后出现骨折的患者。糖皮质激素通过增加骨吸收和降低骨密度而导致骨丢失。 还会导致肌肉丧失和虚弱,从而导致更高的跌倒发生率。综合效应对 骨骼和肌肉是GC骨折风险增加的主要原因。抑制吸收(电流 护理标准)阻止骨丢失;但显著降低骨转换,导致微损伤堆积 有可能发展为颌骨坏死和不典型骨折;并且不能阻止肌肉 软弱。因此,构建新骨并同时干扰的骨合成代谢治疗方法 对于GC来说,肌肉中的作用是非常必要的。导致这一应用程序的工作表明,GC增加 蛋白酶体降解诱导因子E3泛素连接酶阿托金1、MuRF1和MUSA1的表达 (萎缩基因)在肌肉和骨骼中都存在,这是一个新的发现,因为萎缩基因传统上被认为是肌肉特有的。 此外,硼替佐米抑制蛋白酶体的降解可阻止GC诱导的成骨细胞凋亡 此外,Bortezomib或沉默成骨细胞中的MuRF1可阻止GC诱导的基质矿物减少。 体外程序化。此外,维生素D受体(VDR)的激活具有有益的肌肉骨骼效应和 可能会防止摔倒。我们发现VDR信号抑制GC诱导的:1)骨骼和骨骼中的阿托品基因表达 2)SOST在体外的表达增加;3)成骨细胞和骨细胞的凋亡 体外培养。根据这些证据,我们假设阿托品基因上调是一种常见的机制。 骨骼和肌肉中潜在的GC作用以及干扰阿托金表达或 功能将防止GC在这两个组织中的有害行为。我们将使用体内、体外和 体外实验方法。AIM1将检测MuRF1或药物-1的表达或功能的遗传缺失- Bortezomib逻辑抑制蛋白酶体干扰阿托品的表达/功能及其拮抗作用 在预防和修复模型中,GC在体内诱导的骨或肌肉萎缩;以及基因缺失 抑制Notch或FoxO1,或药物抑制Notch信号可预防GC引起的肌肉萎缩。AIM2 将通过研究VDR信号在GC诱导的骨和肌肉萎缩中的作用机制。 VDR信号转导(由1,25-D3或去钙化醇/ED-17诱导的VDR配体是否具有降低的高钙- 小鼠动作)抵消GC对骨骼中蛋白质平衡、线粒体动力学和细胞能量学的调节 和肌肉;通过研究VDR信号是否逆转合成代谢信号和刺激的抑制 Gc基因缺失小鼠骨骼中SOST上调介导的分解代谢信号的研究 肌肉中的VDR(HSA-MerCreMer)和相应的对照窝产仔;并通过确定VDR信号是否 防止GC对肌肉纤维类型组成的影响(糖酵解与氧化),和/或保留Ryn Recep- 托尔介导的肌肉收缩。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways.
  • DOI:
    10.1016/j.abb.2011.12.022
  • 发表时间:
    2012-02-15
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Lezcano V;Bellido T;Plotkin LI;Boland R;Morelli S
  • 通讯作者:
    Morelli S
Role of TGF-β in a mouse model of high turnover renal osteodystrophy.
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
  • DOI:
    10.1158/0008-5472.can-15-1703
  • 发表时间:
    2016-03-01
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Delgado-Calle J;Anderson J;Cregor MD;Hiasa M;Chirgwin JM;Carlesso N;Yoneda T;Mohammad KS;Plotkin LI;Roodman GD;Bellido T
  • 通讯作者:
    Bellido T
Absence of Cx43 selectively from osteocytes enhances responsiveness to mechanical force in mice.
  • DOI:
    10.1002/jor.22341
  • 发表时间:
    2013-07
  • 期刊:
  • 影响因子:
    2.8
  • 作者:
    Bivi, Nicoletta;Pacheco-Costa, Rafael;Brun, Lucas R.;Murphy, Thomas R.;Farlow, Nathan R.;Robling, Alexander G.;Bellido, Teresita;Plotkin, Lilian I.
  • 通讯作者:
    Plotkin, Lilian I.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Teresita M. Bellido其他文献

The development of a collagen-nanoscale hydroxyapatite three-dimensional (3D) emin vitro/em culture system for reproducing osteocyte differentiation and tissue mineralization
用于复制骨细胞分化和组织矿化的胶原蛋白-纳米羟基磷灰石三维(3D)体外培养系统的开发
  • DOI:
    10.1016/j.biomaterials.2025.123451
  • 发表时间:
    2026-01-01
  • 期刊:
  • 影响因子:
    12.900
  • 作者:
    Xiaoyu Xu;Brian T. Golz;Brennan T. Flannery;Maxime A. Gallant;Whitney A. Bullock;Teresita M. Bellido;Eric A. Nauman;Sherry L. Voytik-Harbin;Dianne Little;Russell P. Main
  • 通讯作者:
    Russell P. Main
Allogeneic Mesenchymal Stromal Cells Increase In Vivo Muscle Function and Promote Muscle Fiber Regeneration in a Diabetic Mouse Model of Critical Limb-Threatening Ischemia
  • DOI:
    10.1016/j.jvs.2020.06.057
  • 发表时间:
    2020-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Justin R. King;Katherin E. Leckie;Amy Y. Sato;Teresita M. Bellido;Marlee Yancey;Leni Moldovan;Michael P. Murphy;Steven J. Miller
  • 通讯作者:
    Steven J. Miller

Teresita M. Bellido的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Teresita M. Bellido', 18)}}的其他基金

ASBMR Three Year Pre-Meeting Symposia
ASBMR 三年会前研讨会
  • 批准号:
    10468525
  • 财政年份:
    2022
  • 资助金额:
    $ 33.11万
  • 项目类别:
ASBMR Three Year Pre-Meeting Symposia
ASBMR 三年会前研讨会
  • 批准号:
    10625441
  • 财政年份:
    2022
  • 资助金额:
    $ 33.11万
  • 项目类别:
Glucocorticoid-induced Atrophy in Bone and Muscle
糖皮质激素引起的骨和肌肉萎缩
  • 批准号:
    10301368
  • 财政年份:
    2020
  • 资助金额:
    $ 33.11万
  • 项目类别:
Glucocorticoid-induced Atrophy in Bone and Muscle
糖皮质激素引起的骨和肌肉萎缩
  • 批准号:
    10225876
  • 财政年份:
    2020
  • 资助金额:
    $ 33.11万
  • 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
  • 批准号:
    9911968
  • 财政年份:
    2019
  • 资助金额:
    $ 33.11万
  • 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
  • 批准号:
    10618285
  • 财政年份:
    2019
  • 资助金额:
    $ 33.11万
  • 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
  • 批准号:
    10265416
  • 财政年份:
    2019
  • 资助金额:
    $ 33.11万
  • 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
  • 批准号:
    10328422
  • 财政年份:
    2019
  • 资助金额:
    $ 33.11万
  • 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
  • 批准号:
    9764747
  • 财政年份:
    2019
  • 资助金额:
    $ 33.11万
  • 项目类别:
BLR&D Research Career Scientist Award Application for Teresita Bellido, PhD
BLR
  • 批准号:
    10454217
  • 财政年份:
    2019
  • 资助金额:
    $ 33.11万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
  • 批准号:
    10719415
  • 财政年份:
    2023
  • 资助金额:
    $ 33.11万
  • 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
  • 批准号:
    10585802
  • 财政年份:
    2023
  • 资助金额:
    $ 33.11万
  • 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10605856
  • 财政年份:
    2023
  • 资助金额:
    $ 33.11万
  • 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
  • 批准号:
    23K08773
  • 财政年份:
    2023
  • 资助金额:
    $ 33.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
  • 批准号:
    23K15866
  • 财政年份:
    2023
  • 资助金额:
    $ 33.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10743485
  • 财政年份:
    2023
  • 资助金额:
    $ 33.11万
  • 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
  • 批准号:
    10749797
  • 财政年份:
    2023
  • 资助金额:
    $ 33.11万
  • 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
  • 批准号:
    22K09076
  • 财政年份:
    2022
  • 资助金额:
    $ 33.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
  • 批准号:
    10583516
  • 财政年份:
    2022
  • 资助金额:
    $ 33.11万
  • 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
  • 批准号:
    RGPIN-2019-05371
  • 财政年份:
    2022
  • 资助金额:
    $ 33.11万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了